Treating Posttransplant Anemia With Erythropoietin Improves Quality of Life but Does Not Affect Progression of Chronic Kidney Disease

Pile, Taryn; Raftery, Martin; Thuraisingham, Raj; Kirwan, Christopher; Harwood, Steven; Yaqoob, M.

doi:10.6002/ect.2018.0283

Cited by 11 publications

(9 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…34 Finally, early preventive strategy on anemia control has the prospect of enhancing physical well-being and reducing the utilization of health resources in transplant recipients. [35][36][37] As shown in similar studies, although not statistically significant in our cohort, subjects treated with intravenous iron had a lower rate of ARE, infections, and hospitalizations. 1,3,6,38,39 In a study by Schechter et al, 40 anemia was also likely to occur in the context of ARE, and the occurrence of both events increased the likelihood of future graft loss and mortality rate by 6-fold and 9-fold, respectively.…”

Section: Primary Renal Pathologysupporting

confidence: 78%

“…Finally, early preventive strategy on anemia control has the prospect of enhancing physical well‐being and reducing the utilization of health resources in transplant recipients 35‐37 . As shown in similar studies, although not statistically significant in our cohort, subjects treated with intravenous iron had a lower rate of ARE, infections, and hospitalizations 1,3,6,38,39 .…”

Section: Discussionsupporting

confidence: 65%

See 1 more Smart Citation

Impact of immediate post‐transplant parenteral iron therapy on the prevalence of anemia and short‐term allograft function in a cohort of pediatric and adolescent renal transplant recipients

Iorember

Avilés

Bamgbola

2020

Pediatric Transplantation

View full text Add to dashboard Cite

The prevalence of anemia after a recent KTX surgery in adults ranges from 70% to 90%, while the incidence of late-onset anemia is 20%-50%. 1-3 Similarly, in a few available pediatric studies, the prevalence of anemia was reported as 84% in the first month of transplant and 25%-50% at 12 months. 4-6 Unfortunately, due to a widespread under-diagnosis of post-transplant anemia (PTA), inadequate treatment is a frequent phenomenon. 1,7 However, early-and late-onset PTAs have been associated with a high all-cause mortality rate and shorter duration of allograft survival. 2,6,8-11 Due to a high turnover rate of iron during chronic dialysis and because of peri-surgical blood loss, ID is the major cause of early-onset anemia. 7,12-14 On the other hand, late-onset anemia (>12 month post-transplant) is principally driven by inadequate nutrition and EPO deficiency that results from impaired allograft function. 3,15,16

show abstract

Section: Primary Renal Pathologysupporting

confidence: 78%

Section: Discussionsupporting

confidence: 65%

Impact of immediate post‐transplant parenteral iron therapy on the prevalence of anemia and short‐term allograft function in a cohort of pediatric and adolescent renal transplant recipients

Iorember

Avilés

Bamgbola

2020

Pediatric Transplantation

View full text Add to dashboard Cite

show abstract

“…83 However, one single-center study showed no change in the rate of decline in allograft function over 2 years with epoetin beta therapy (target hemoglobin, 11.5-13.5 g/dl). 84 In this study, significantly greater improvements in the vitality and mental health domains of the Short Form Health Survey were observed with epoetin beta versus no ESA therapy. 84 Of note, a retrospective study of 1794 patients who underwent kidney transplantation suggested that ESA therapy may increase the risk of mortality among those with higher (>14.0 g/dl) and lower (<12.5 g/dl) hemoglobin levels compared with a reference hemoglobin level of 12.5 g/dl.…”

Section: Management Of Post-transplant Anemiamentioning

confidence: 52%

“…84 In this study, significantly greater improvements in the vitality and mental health domains of the Short Form Health Survey were observed with epoetin beta versus no ESA therapy. 84 Of note, a retrospective study of 1794 patients who underwent kidney transplantation suggested that ESA therapy may increase the risk of mortality among those with higher (>14.0 g/dl) and lower (<12.5 g/dl) hemoglobin levels compared with a reference hemoglobin level of 12.5 g/dl. 85 In patients not receiving ESAs, hemoglobin levels <12.5 g/dl were associated with an increased mortality risk, whereas higher hemoglobin levels were associated with a reduced risk.…”

Section: Management Of Post-transplant Anemiamentioning

confidence: 52%

Treatment of anemia in difficult-to-manage patients with chronic kidney disease

Raichoudhury

Spinowitz

2021

Kidney International Supplements

View full text Add to dashboard Cite

The management of anemia of chronic kidney disease (CKD) is often challenging. In particular, for patients with underlying inflammation, comorbid type 2 diabetes or cancer, those hospitalized, and recipients of a kidney transplant, the management of anemia may be suboptimal. Responsiveness to iron and/or erythropoiesis-stimulating agents, the mainstay of current therapy, may be reduced and the risk of adverse reactions to treatment is increased in these difficult-to-manage patients with anemia of CKD. This review discusses the unique patient and disease characteristics leading to complications and suboptimal treatment response. New treatment options in clinical development, such as hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitors, may be particularly useful for difficult-to-treat patients. In clinical studies, HIF-PH inhibitors provided increased hemoglobin levels and improved iron utilization in anemic patients with nondialysis-dependent and dialysis-dependent CKD, and preliminary data suggest that HIF-PH inhibitors may be equally effective in patients with or without underlying inflammation. The availability of new treatment options, including HIF-PH inhibitors, may improve treatment outcomes in difficult-to-manage patients with anemia of CKD.

show abstract

“…Furthermore, Wnt4 and several Wnt/β-catenin target genes are highly expressed in the medullary interstitium of the kidney [ 69 ]. Wnt4 is also expressed in the medullary stroma and plays an important role in kidney medullary morphogenesis.…”

Section: Wnt Signaling In Kidney Developmentmentioning

confidence: 99%

Wnt signaling in kidney: the initiator or terminator?

et al. 2020

View full text Add to dashboard Cite

The kidney is a key organ in the human body that excretes toxins and sustains the water–electrolyte balance. During embryonic development and disease progression, the kidney undergoes enormous changes in macrostructure, accompanied by a variety of microstructural histological changes, such as glomerular formation and sclerosis, tubule elongation and atrophy, interstitial establishment, and fibrosis progression. All of these rely on the frequent occurrence of cell death and growth. Notably, to overcome disease, some cells regenerate through self-repair or progenitor cell differentiation. However, the signaling mechanisms underlying kidney development and regeneration have not been elucidated. Recently, Wnt signaling has been noted to play an important role. Although it is a well-known developmental signal, the role of Wnt signaling in kidney development and regeneration is not well recognized. In this review, we review the role of Wnt signaling in kidney embryonic development, tissue repair, cell division, and progenitor cell differentiation after injury. Moreover, we briefly highlight advances in our understanding of the pathogenic mechanisms of Wnt signaling in mediating cellular senescence in kidney parenchymal and stem cells, an irreversible arrest of cell proliferation blocking tissue repair and regeneration. We also highlight the therapeutic targets of Wnt signaling in kidney diseases and provide important clues for clinical strategies.

show abstract

Treating Posttransplant Anemia With Erythropoietin Improves Quality of Life but Does Not Affect Progression of Chronic Kidney Disease

Cited by 11 publications

References 18 publications

Impact of immediate post‐transplant parenteral iron therapy on the prevalence of anemia and short‐term allograft function in a cohort of pediatric and adolescent renal transplant recipients

Impact of immediate post‐transplant parenteral iron therapy on the prevalence of anemia and short‐term allograft function in a cohort of pediatric and adolescent renal transplant recipients

Treatment of anemia in difficult-to-manage patients with chronic kidney disease

Wnt signaling in kidney: the initiator or terminator?

Contact Info

Product

Resources

About